a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with INZY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then INZY could also see price increases.
Ticker / NAME | Correlation To PDSB | 1D Price Change % | ||
---|---|---|---|---|
PDSB | 100% | -5.63% | ||
INZY - PDSB | 38% Loosely correlated | -5.60% | ||
ACLX - PDSB | 38% Loosely correlated | -3.81% | ||
RXRX - PDSB | 37% Loosely correlated | -16.62% | ||
MNKD - PDSB | 37% Loosely correlated | -2.88% | ||
KNSA - PDSB | 36% Loosely correlated | -2.73% | ||
More |
Ticker / NAME | Correlation To PDSB | 1D Price Change % |
---|---|---|
PDSB | 100% | -5.63% |
cancer theme (87 stocks) | 48% Loosely correlated | +0.89% |
pharmaceuticals theme (167 stocks) | 35% Loosely correlated | +0.82% |
immunotherapy theme (13 stocks) | 30% Poorly correlated | -0.95% |